Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants.

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2025-02-10 DOI:10.3390/vaccines13020171

Andreea Calomfirescu-Avramescu, Adrian Ioan Toma, Claudia Mehedințu, Leonard Năstase, Vlad Dima

{"title":"Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants.","authors":"Andreea Calomfirescu-Avramescu, Adrian Ioan Toma, Claudia Mehedințu, Leonard Năstase, Vlad Dima","doi":"10.3390/vaccines13020171","DOIUrl":null,"url":null,"abstract":"Background: In 2022, Romania started an RSV immunoprophylaxis program with Palivizumab for infants at high risk: preterm infants born before 35 weeks of pregnancy, infants born with congenital heart defects, and infants with chronic lung disease. We evaluated treatment adherence from August 2022 to March 2024.Method: We monitored the increase in the number of patients enrolled in the program and the number of collaborating neonatologists, family doctors, and pediatricians. Adherence to all doses of Palivizumab in enrolled patients was assessed by telephone interviews. The factors contributing to reduced adherence were identified.Results: Between August 2022 and March 2024, 1903 patients and 233 specialists were enrolled, a steady increase in both cohorts. The percentage of patients that complete their full sequence of doses decreases along with the number of doses (99% for one dose, 73% for two doses, 47% for three doses, 35% for four doses, and 22% for five doses) due to several factors.Conclusions: The program remains highly regarded by both physicians and caregivers, demonstrating its effectiveness as a valuable resource for educating parents and facilitating monoclonal antibody administration as a prevention method for RSV.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 2","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861343/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13020171","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In 2022, Romania started an RSV immunoprophylaxis program with Palivizumab for infants at high risk: preterm infants born before 35 weeks of pregnancy, infants born with congenital heart defects, and infants with chronic lung disease. We evaluated treatment adherence from August 2022 to March 2024.

Method: We monitored the increase in the number of patients enrolled in the program and the number of collaborating neonatologists, family doctors, and pediatricians. Adherence to all doses of Palivizumab in enrolled patients was assessed by telephone interviews. The factors contributing to reduced adherence were identified.

Results: Between August 2022 and March 2024, 1903 patients and 233 specialists were enrolled, a steady increase in both cohorts. The percentage of patients that complete their full sequence of doses decreases along with the number of doses (99% for one dose, 73% for two doses, 47% for three doses, 35% for four doses, and 22% for five doses) due to several factors.

Conclusions: The program remains highly regarded by both physicians and caregivers, demonstrating its effectiveness as a valuable resource for educating parents and facilitating monoclonal antibody administration as a prevention method for RSV.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.